UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 6, 2006

<u>Lifeline Therapeutics, Inc.</u> (Exact name of registrant as specified in its charter)

Colorado	000-30489	90-0224471
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
640	O South Fiddler's Green Circle, Suite 1970, Greenwood Village, (Address of principal executive offices) (Zip Code)	CO 80111
	Registrant's telephone number, including area code: (720) 488-	<u>1711</u>
	(Former name or former address, if changed since last report	t)
Check the appropriate box below if the Fort provisions (see General Instruction A.2. below	n 8-K filing is intended to simultaneously satisfy the filing obligation):	ation of the registrant under any of the following
Written communications pursuant to Rule	425 under the Securities Act (17 CFR 230.425)	
o Soliciting material pursuant to Rule 14a-1	2 under the Exchange Act (17 CFR 240.14a-12)	
Pre-commencement communications purs	uant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-	-2(b))
o Pre-commencement communications purs	uant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-	4(c))

ITEM 7.01 Regulation FD Disclosure

Beginning December 6, 2006 and thereafter, management of the company intends to hold discussions and/or meetings with investors. The attached presentation, dated December 2006, includes the information to be discussed. The presentation is attached as Exhibit 99.1 hereto.

ITEM 9.01. Exhibits

99.1 Presentation entitled "IR Presentation".

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: December 6, 2006

LIFELINE THERAPEUTICS, INC.

By: /s/ Stephen K. Onody Stephen K. Onody Chief Executive Officer

Exhibit Index

Exhibit Number Description

99.1 Presentation entitled "IR Presentation".



Dedicated to helping people reach their health and wellness goals with science-based natural solutions.

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Statements in this presentation which are not statements of historical fact are "forward-looking statements" within the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on information available to, and the expectations and assumptions deemed reasonable by Lifevantage Corporation (the "Company") at the time this presentation was made. Although the Company believes that the assumptions underlying such statements are reasonable, it can give no assurance that they will be attained. Factors that could cause actual results to differ materially from expectations include the risks detailed under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-KSB, and risks identified in the Company's quarterly reports on Form 10-QSB and in other materials filed by the Company from time to time with the Securities and Exchange Commission.

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Building A Company - Goals

- · Increase sales
- · Stay true to science
- Customer Service
- Increase shareholder value

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



A Challenging Year

- Financial Performance
- Market Opportunity
- Product and Science
- Initiatives
 - Sales and Distribution
 - Marketing
- Looking Ahead

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Building A Company – Finance and Operations

- Virtual Partners: Chemins, UPS
- eCommerce Model
- · Financial and Regulatory Achievements
 - · Hired new financial staff
 - · CFO, Jerry Houston
 - · Director of Finance, Brad Amman
 - SEC SB2 Registration
 understanding reached November 10, 2006
 - · Patent Valuation \$2M vs. Goodwill
 - Accounting Issues Cleared
 - SEC Retail Revenue Recognition 12 Months Early
 - Reporting Filings at or in advance of due dates
 - Initiated Quarterly Conference Calls and Shareholder Briefings
 - Initiated IR Coverage: Taglich Brothers, Catalyst Fin Resources

December 2006

Lifevantage Corporation LFLT.OB IR Presentation

Operating Results
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
For the fiscal years ended June 30, 2006 and 2005



	June 30, 2006	June 30, 2005
Revenues:		
Direct Sales, net	\$ 7,165,	819 \$ 2,353,795
Retail Sales, net		
Total Sales, net	7, 165,	819 2,353,795
Cost of sales	1,491,	332 393,551
Gross profit	5,674,	487 1,960,244
Operating expenses:		
Marketing and customer service	4,259,	711 923,774
General and administrative	3,904,	
Research and development	114,	,163 37,933
Depreciation and amortization		,279 101,596
Total operating expenses	8,543,	521 4,045,057
Operating income (loss)	(2,869,	034) (2,084,813)
Other income and (expense):		
Interest income (expense)	134,	,533 (100,563)
Amort, of debt and stock offering costs		- (447,132)
Beneficial conversion (expense)		- (3,185,105)
Other (expenses)		- (4,784)
Net other income (expense)	134,	,533 (3,737,584)
Net (loss)	\$ (2,734,	501) \$ (5,822,397)
Net (loss) per share, basic and diluted	(\$1	0.12) (\$0.33)
Weighted average shares outstanding	22,117,	992 17,583,562

December 2006

Lifevantage Corporation LFLT.OB IR Presentation

Balance Sheets

CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2006 and 2005 (Restated *, Unaudited)

and 2005 (Restated *, Unaudited)		
	June 30,	June 30,
	2006	2005
<u>ASSETS</u>		
Current assets	4,414,215	6,032,346
Property and equipment, net	245,000	200,944
Intangible assets, net	2,162,042	2,268,830
Deposits	316,621	31,192
TOTAL ASSETS	\$7,137,878	\$8,533,312
LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities		
Accounts payable	\$613,833	\$657,528
Accrued expenses	399,305	207,672
Deferred revenue	1,144,950	
Capital lease-current portion	1,985	
Total Current Liabilities	2,160,073	865,200
Long-Term Liabilities		
Capital lease-long term portion	3,146	-
Total Liabilities	2,163,219	865,200
Stockholders' Equity		
Common Stock, Series A -par value \$.001, 250,000,000		
shares authorized, 22,117,992 issued and outstanding	22,118	22,118
Additional paid-in capital	14,018,487	13,921,832
Accumulated (deficit)	(9,010,339)	(6,275,838)
Unrealized (loss) on securities available for sale	(55,607)	7.000.440
Total stockholders' equity	4,974,659	7,668,112
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$7,137,878	\$8,533,312

December 2006

* Reflects restatement

Lifevantage Corporation LFLT.OB IR Presentation

7

Protandim

Operating Results
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
For the three months ended September 30, 2006 and 2005



For the three months ended			
Septe	mber 30, 2006	Septem	ber 30, 2005
\$	896,689	\$	2,964,591
	1,178,793		
	2,075,482		2,964,591
	375,552		596,561
	1,699,930		2,368,030
	1,032,815 1,407,626 65,683		1,144,470 1,065,409 - 86,374
			2,296,253
	(835,626)		71,777
	15,418		8,538
\$	(820,208)	\$	80,315
	(\$0.04)		\$0.00
	22,118,034		22,117,992
	\$	\$ 896,689 1,178,793 2,075,482 375,552 1,699,930 1,032,815 1,407,626 65,683 29,432 2,535,556 (835,626) 15,418 \$ (820,208)	\$ 896,689 \$ 1,178,793

December 2006

Lifevantage Corporation LFLT.OB IR Presentation

Operating Results
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
For the three months ended September 30, 2006 and June 30, 2006



	For the three months ended				
	Septe	September 30, 2006		June 30, 2006	
Revenues:					
Direct Sales, net	\$	896,689	\$	1,098,852	
Retail Sales, net		1,178,793		-	
Total Sales, net		2,075,482		1,098,852	
Cost of sales		375,552		235,641	
Gross profit		1,699,930		863,211	
Operating expenses:					
Marketing and customer service		1,032,815		1,587,680	
General and administrative		1,407,626		800,386	
Research and development		65,683		65,887	
Depreciation and amortization		29,432		26,990	
Total operating expenses		2,535,556		2,480,943	
Operating income (loss)		(835,626)		(1,617,732)	
Net other income and (expense)		15,418		44,873	
Net (loss)	\$	(820,208)	\$	(1,572,859)	
Net (loss) per share, basic and diluted		(\$0.04)		(\$0.07)	
Weighted average shares outstanding		22,118,034		22,117,992	

December 2006

Lifevantage Corporation LFLT.OB IR Presentation

Balance Sheets

CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2006 and 2005 (Restated *, Unaudited)



	ocptombol ou,	ounc oo,
	2006	2006
<u>ASSETS</u>		
Current assets	4,375,562	4,414,215
Property and Equipment, net	254,088	245,000
Intangible Assets, net	2,199,412	2,162,042
Deposits	325,440	316,621
TOTAL ASSETS	\$7,154,502	\$7,137,878
LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities		
Accounts payable	\$645,137	\$613,833
Accrued expenses	305,833	399,305
Margin debt payable	607,487	-
D eferred revenue	876,660	1,144,950
Capital lease-current portion	2,059	1,985
Total Current Liabilities	2,437,176	2,160,073
Long-Term Liabilities		
Capital lease-long term portion	2,603	3,146
Total Liabilities	2,439,779	2,163,219
Stockholders' Equity		
Common Stock, Series A -par value \$.001, 250,000,000		
shares authorized, 22,118,034 issued and outstanding	22,118	22,118
Additional paid-in capital	14,542,396	14,018,487
Accumulated (deficit)	(9,830,547)	(9,010,339)
Unrealized (loss) on securities available for sale	(19,244)	(55,607)
Total stockholders' equity	4,714,723	4,974,659
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$7,154,502	\$7,137,878

* Reflects restatement December 2006 Lifevantage Corporation LFLT.OB IR Presentation



Building A Company

Market Opportunity

High Growth Target Market


December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Market Opportunity: World-wide Nutraceutical / Supplement Market ~ \$40B

(Courtesy of Bathgate Capital Partners)



Market Segments (Courtesy of Bathgate Capital Partners)



U.S. Condition - Specific Supplement Sales: 2003 - 2005

	2003 Sales	2004 Sales	2005 Sales	2005 Growth	% 2005 Total
Sports/Energy/Weight Loss	5,760	5,664	5,683	0.3%	27%
General Health Protar	dim 4,340	4,453	4,580	2.8%	22%
Joint Health	1,097	1,105	1,138	3.0%	5%
Cold / Flu-Immune	957	996	1,028	3.2%	5%
Anti-cancer	858	926	1,006	8.6%	5%
Heart Health	884	957	1,002	4.7%	5%
Bone Health	1,022	980	972	-0.8%	5%
Gastrointestinal Health	536	591	633	7.0%	3%
Diabetes	466	501	519	3.7%	1%
Menopause	297	289	273	-5.4%	1%
Top Conditions	16,217	16,462	16,834	2.3%	81%
Others	3,586	3,862	4,008	3.8%	19%
Total Supplements	19,803	20,324	20,842	2.5%	100 %


Source: Nutritional Business Journal

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



The U.S. Supplement Market by Outlet



Nutrition Business Journal, June/July 2006

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Building A Company

Product and Science

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



The Problem - Summary of Oxidative Stress

- Oxidative stress (cell damage) occurs when oxidative balance is upset by increased production of oxidants, or by decreased availability of antioxidants
- Humans produce a number of antioxidant enzymes naturally: superoxide dismutase (SOD) and catalase (CAT) are the most important
- · Humans produce about 0.3 mole of free radicals daily
- As people age, the body's natural production of SOD and CAT enzymes does not keep up with increasing levels of free radicals

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



The Science of Oxidative Stress

- Oxidative stress is associated with over 100 diseases, as presented in more than 44,000 peerreviewed, published, scientific papers
- Examples of areas where oxidative stress appears to play a role, based on these papers, include:
 - ➤ Heart disease
 - ➤ Diabetes
 - ➤ Cancer

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Yesterday's Solution

- Consumable antioxidants (e.g. vitamins C and E) neutralize only a small fraction of the free radicals/oxidants produced daily
- One gram of vitamin C per day can neutralize about 1/30th of the body's daily production of free radicals per day
 - This assumes full absorption and complete reaction prior to excretion

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Our Solution


- Protandim[®] patent-pending formula
- Protandim[®] triggers our bodies to produce increased levels of our own antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) to reduce the harmful effects of oxidative stress.
- Protandim[®] delivers significantly greater antioxidant benefits than is possible with conventional stoichiometric antioxidant supplements.

December 2006

Lifevantage Corporation LFLT.OB IR Presentation




Traditional antioxidant supplements in normal healthy humans do not affect oxidative stress levels






Normal subjects <u>before</u> supplementation with Protandim showed a strong age-dependent increase in TBARS





22

TBARS dropped an average of 40% (p < 0.0001) after 30 days of Protandim supplementation and the age-related increase in TBARS virtually disappeared



Lifevantage Corporation LFLT.OB

IR Presentation

December 2006



Protandim® Study Conclusion

Causing induction of SOD and CAT to decrease oxidative stress and lipid peroxidation *in vivo* is a much more effective approach than conventional antioxidant supplements.

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Stay True to the Science Additional Studies Underway:

The topics under investigation deal with the alleviation of oxidative stress under the following conditions:

Heart disease

Asthma

Duchenne muscular dystrophy

Metabolic syndrome

Non-alcoholic fatty liver disease

Optic neuropathy Altitude sickness Skin cancer

Photoaging of the skin

Renal failure Osteoarthritis

HIV/AIDS-associated lipodystrophy

Pulmonary hypertension

Hepatitis C

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Building A Company

Initiatives

- · Sales and Distribution
- · Web and eCommerce
- Marketing and PR

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Building A Company – Sales and Distribution

Distribution expanded













 International broker signed for Asian and certain European markets

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Web and e-Commerce

- Installed new e-commerce tools and redesigned web site to:
 - allow our direct customers to better manage their accounts
 - significantly improve communication with our customers
 - allow us to offer new programs to our customers
 - offer expanded content and value added materials to our customers

December 2006

Lifevantage Corporation LFLT.OB IR Presentation





December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Building A Company – Marketing and PR

- Invested in marketing research, sales, and co-marketing activities
 - Market research involved approximately 2,500 health and wellness consumers, and specialized health and wellness focus groups.
 - Findings led to changes in messaging, marketing materials, logo and packaging
 - Featured on PBS Healing Quest
 - Radio, print, and on-line advertising seen or heard by
 - an estimated 98,000,000 people

December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Marketing and PR

Featured twice on



Presented by Elizabeth Somer

- Seen by an estimated 4,700,000 people each time (July 25th and November 9th)
- Increased website traffic

Regional television coverage in 16 markets seen by an estimated 436,000 people

- "Eat your fruits and vegetables and take Protandim®. Give it the one-two punch."
- "Build up your antioxidant arsenal to fight free radicals with Protandim®.




December 2006

Lifevantage Corporation LFLT.OB IR Presentation



New logo and packaging






December 2006


Lifevantage Corporation LFLT.OB IR Presentation

New print advertising





Ads tagged with GNC & CVS



December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Consumer and Professional



December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Marketing and PR









December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Looking Ahead – Key Strategy Channels

- · Additional Retail
- · Scientific Studies
- · Licensing and OEM
- Direct Response TV
- International Distribution
- · Multi-level Marketing
- Brokers
- · Line Extensions
- New Products



December 2006

Lifevantage Corporation LFLT.OB IR Presentation



Summary

- · High Growth Target Market
- · Science and Evidence Based
- · Strong Gross Margins
- · No Long-Term Debt
- Virtual Company
- · Evolving Distribution Model
- · Focused Marketing and PR

December 2006

Lifevantage Corporation LFLT.OB IR Presentation